A study has identified novel biomarkers that distinguish between active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and remission. Monach et al. measured levels of 28 serum proteins in patients before and 6 months after treatment in a large clinical trial of AAV. Data from the 137 patients in remission at month 6 showed that levels of 24 of the biomarkers were significantly different to levels at screening. CXCL13, MMP-3 and TIMP-1 were the biomarkers that best discriminated between active disease and remission.
ORIGINAL RESEARCH PAPER
Monach, P. A. et al. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-201981
Rights and permissions
About this article
Cite this article
Biomarkers for staging ANCA-associated vasculitis activity. Nat Rev Nephrol 8, 613 (2012). https://doi.org/10.1038/nrneph.2012.209
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.209